Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Obama to meet lawmakers in attempt to protect health law: Politico

President Barack Obama plans to meet with Democratic lawmakers in Congress to discuss how to protect his signature healthcare law from Republican efforts to dismantle it, Politico reported.

Read More »

More work lies ahead to fight Zika, other threats: CDC chief

A year ago, the mosquito-borne Zika virus was only beginning to reveal itself as a threat to pregnant women and their unborn babies. Since then, U.S. officials have issued 60 travel alerts along with guidance for athletes and tourists traveling to the Olympics in Rio. They have also deployed more than 1,000 experts to Puerto Rico and elsewhere, tested more than 147,000 lab specimens, initiated 25 major studies and issued more than 230 scientific publications. And the work is not done, said Dr. Thomas Frieden, director of the U.S. Centers for Disease Control and Prevention.

Read More »

Growth hormone deficiency drug fails study

OPKO Health Inc. said its experimental drug for GHD in adults failed to provide a statistically significant benefit over a placebo in a late-stage study.

Read More »

Dietary magnesium tied to lower risk of heart disease and diabetes

A diet rich in magnesium – found in foods like leafy greens, fish, nuts and whole grains – may help lower the risk of chronic health problems like heart disease and diabetes, a research review suggests.

Read More »

7 Juicy Acquisition Targets in Biopharma for 2017

2016 was not a banner year for M&A in the biopharma industry compared to 2014 and 2015. BioPharmaDIVE looks at seven potential acquisition targets for 2017.

Read More »

Innocoll Shares Tumble After FDA’s Refusal to File Xaracoll NDA

Innocoll received a Refusal to File letter from the United States Food and Drug Administration (FDA) for XARACOLL, the company’s product candidate for the treatment of postsurgical pain.

Read More »

“Hidden’ celiac disease less common now in U.S.

Fewer people in the U.S. have celiac disease without realizing it, a new study finds.

Read More »

Web-based therapy relieves insomnia

Web-based therapy for insomnia is an effective option that could reach “previously unimaginable numbers of people,” researchers suggest.

Read More »

FDA rejects Cempra’s antibiotic for pneumonia

The FDA rejected Cempra Inc.’s antibiotic for community-acquired bacterial pneumonia, citing inadequate data on the drug’s impact on liver and manufacturing issues.

Read More »

Like It or Not: Here’s How Much Biogen’s Spinraza Will Cost

Biogen finally set a price tag for its newly approved spinal atrophy drug Spinraza – the first drug ever approved for the disease – and as expected, it’s in the high six figures.

Read More »

Fortress Biotech Surged After Reporting Big Success With CAR-T Cancer Approach

Shares of Fortress Biotech (formerly known as Coronado Biosciences) surged after the company announced that a glioblastoma patient who showed no response to standard of care treatments had a remarkable turnaround after being treated with the company’s Phase I drug candidate, MB-101.

Read More »

Provectus Fires Peter Culpepper as Interim CEO and COO

For the second time in less than a year, Provectus Biopharmaceuticals Inc. is down a chief executive officer.

Read More »

FTC requires divestitures in Boehringer-Sanofi deal

Boehringer Ingelheim agreed to divest five types of animal health products to settle charges that a proposed asset swap with Sanofi would harm competition.

Read More »

Medtronic must face revived U.S. lawsuit over Infuse

A federal appeals court revived a lawsuit accusing Medtronic Plc of defrauding shareholders by covering up negative side effects from its Infuse bone growth product for nearly a decade.

Read More »

Up-and-Coming Tedor Pharma Expands and Adds New Jobs

Tedor Pharmaceuticals is expanding its Rhode Island manufacturing facility and expanding its employment with more than 20 new positions, the company announced.

Read More »

A Turnaround: Regeneron Eyes a Comeback in 2017

After suffering a setback in 2016, Regeneron could be poised for a turnaround in 2017 and it hinges on correcting manufacturing problems that caused regulators to block approval of a new drug to treat rheumatoid arthritis.

Read More »

Top Harvard Scientist Retracts Diabetes Breakthrough Paper

A Harvard professor has retracted research that was once considered a breakthrough in diabetes research.

Read More »

Serial testers and cursory checks: India’s flawed generic drug trials business

The serial testing of some volunteers is raising new questions about the level of oversight of India’s generic drug trials industry, after some CROs came under recent international regulatory scrutiny.

Read More »

Anthera’s cystic fibrosis drug fails late-stage study, shares tank

Anthera Pharmaceuticals Inc. said its drug to treat certain cystic fibrosis patients failed a late-stage study, sending the company’s shares tumbling nearly 70 percent in after-hours trading.

Read More »

U.S. posts rules for addressing cyber bugs in medical devices

The U.S. government issued rules for addressing cyber vulnerabilities in medical devices, providing manufacturers with guidelines for fixing security bugs in equipment, including pacemakers, insulin pumps and imaging systems.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom